1. Targeted therapy for pediatric low-grade glioma
   Juan Pablo Muñoz Pérez et al, 2021, Child's Nervous System CrossRef
2. BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation
   Drishti Rathod et al, 2019, European Journal of Pharmaceutical Sciences CrossRef
3. Novel Targeted Therapies for Metastatic Thyroid Cancer—A Comprehensive Review
   Mohammad Al-Jundi et al, 2020, Cancers CrossRef
4. Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies
   Christopher J. Fay et al, 2023, American Journal of Clinical Dermatology CrossRef
5. Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma
   Vinita Ruth Sundaram et al, 2018, Medicine CrossRef
6. Bimodal regulation of the PRC2 complex by USP7 underlies tumorigenesis
   Dongxue Su et al, 2021, Nucleic Acids Research CrossRef
7. Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond
   Maria E Cabanillas et al, 2019, Endocrine Reviews CrossRef
8. Dermatological Drugs, Topical Agents, and Cosmetics
   Adrienne T. Black, 2017, A Worldwide Yearly Survey of New Data in Adverse Drug Reactions CrossRef
9. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)
   M. Reinwald et al, 2018, Clinical Microbiology and Infection CrossRef
10. Reacciones capilares de las nuevas terapias diana dirigidas contra el cáncer
    J.F. Mir-Bonafé et al, 2019, Actas Dermo-Sifiliográficas CrossRef
11. A Network Meta‐Analysis of Short and Long‐Term Efficacy of Targeted Therapy With Single or Double‐Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials
    Ting Xie et al, 2018, Journal of Cellular Biochemistry CrossRef
12. The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis
    Peng Chen et al, 2019, Cutaneous and Ocular Toxicology CrossRef
13. Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis
    Ying Yang et al, 2021, Cancer Research and Treatment CrossRef
14. E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers
    Hong-Beom Park et al, 2022, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
15. Binding Kinetics Survey of the Drugged Kinome
    Victoria Georgi et al, 2018, Journal of the American Chemical Society CrossRef
16. Concise genetic profile of lung carcinoma
    Srikanth Umakanthan et al, 2023, Postgraduate Medical Journal CrossRef
17. Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling
    Zhengyun Zou et al, 2020, Pigment Cell & Melanoma Research CrossRef
18. Changes in the Transcriptome and Chromatin Landscape in BRAFi-Resistant Melanoma Cells
    Kiran Kumar Reddi et al, 2022, Frontiers in Oncology CrossRef
19. Adverse Hair Reactions to New Targeted Therapies for Cancer
    J.F. Mir-Bonafé et al, 2019, Actas Dermo-Sifiliográficas (English Edition) CrossRef